Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Gregory Chow

Orthopaedic Surgery of the Spine Honolulu, HI Medical Doctor

NPI 1164484010 CMS profile 188697

405 N Kuakini St, Honolulu, HI 96817

Open in the dashboard

General payments

$401

15 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gregory Chow of Honolulu, HI is reported in the CMS Open Payments database as having received $401 across 15 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 11th percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $300 10
2024 General $22 1
2023 General $62 3
2021 General $17 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Chow
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Gregory Chow were reported at $300. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Gregory Chow Orthopaedic Surgery of the Spine median Middle half National median
2019 $0 $2,106 $337–$18,608 $163
2020 $0 $1,213 $156–$15,082 $114
2021 $17 $1,834 $271–$15,617 $132
2022 $0 $2,015 $320–$17,036 $149
2023 $62 $1,925 $336–$14,599 $160
2024 $22 $2,110 $341–$12,483 $164
2025 $300 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. DePuy Synthes Sales Inc. $322 11 payments
  2. Medical Device Business Services, Inc. $62 3 payments
  3. Stryker Corporation $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $401 15 payments
Products named General payments · program years 2021–2025
  1. ACF $82 2 payments
  2. SYMPHONY $75 3 payments
  3. TRIALTIS $71 3 payments
  4. CONDUIT $62 3 payments
  5. USS $56 2 payments
  6. CONFIDENCE SPINAL CEMENT SYSTEM $33 1 payment
  7. SPINEJACK $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

421

Median for Orthopedic Surgery: 203

Drug cost

$16,511

Median for Orthopedic Surgery: $1,433

Branded share of claims

48.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 11 $8,529
Calcitonin-Salmon Calcitonin,salmon,synthetic Brand 50 $3,620
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 63 $1,047
Alprazolam Generic 15 $754
Gabapentin Generic 59 $629
Oxycodone Hcl Generic 41 $477
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 79 $348
Alendronate Sodium Generic 14 $343
Zolpidem Tartrate Generic 16 $317
Methylprednisolone Generic 32 $316

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$185,928

Of which drugs: $131

Medicare patients

302

Average age 79

Services billed

1,755

173 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Chronic kidney disease 44%
Osteoporosis 37%
Diabetes 36%
Ischemic heart disease 26%
Atrial fibrillation 19%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 11 1,040 $109

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

15 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery of the Spine in Hawaii

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record